Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
26.79
+0.15 (0.56%)
At close: Apr 28, 2026, 4:00 PM EDT
27.32
+0.53 (1.98%)
After-hours: Apr 28, 2026, 7:17 PM EDT
Genmab Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Genmab stock have an average target of 39.81, with a low estimate of 32 and a high estimate of 48. The average target predicts an increase of 48.60% from the current stock price of 26.79.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for Genmab stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $32 | Buy | Initiates | $32 | +19.45% | Mar 27, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $40 | Buy | Initiates | $40 | +49.31% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +49.31% | Feb 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +49.31% | Feb 18, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +54.91% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
4.38B
from 3.72B
Increased by 17.85%
Revenue Next Year
5.09B
from 4.38B
Increased by 16.04%
EPS This Year
12.31
from 15.37
Decreased by -19.89%
EPS Next Year
17.22
from 12.31
Increased by 39.83%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.7B | 5.6B | ||||||
| Avg | 4.4B | 5.1B | ||||||
| Low | 3.6B | 4.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.2% | 27.6% | ||||||
| Avg | 17.8% | 16.0% | ||||||
| Low | -2.5% | -4.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.02 | 22.92 | ||||||
| Avg | 12.31 | 17.22 | ||||||
| Low | 10.28 | 9.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 23.7% | 86.2% | ||||||
| Avg | -19.9% | 39.8% | ||||||
| Low | -33.1% | -20.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.